Combination of genetic polymorphisms in TLR influence cytokine profile in HCV patients treated with DAAs in the State of Amazonas. (June 2020)

• Record Type: Journal Article
• Authors: Tarragô, Andréa Monteiro; da Silva Neto, Pedro Vieira; Ramasawmy, Rajendranath; Pereira, Grenda Leite; Toro, Diana Mota; de Amorim Xabregas, Lilyane; Costa, Allyson Guimaraes; Victória, Marilú Barbieri; da Silva Victória, Flamir; Malheiro, Adriana
• Is Part Of: Cytokine. Volume 130(2020)
• Publication Date: 2020-06
• Subjects: Hepatitis C -- Polymorphisms -- Toll-like receptor -- Hepatocellular carcinoma -- DAAs; Cytokines -- Periodicals; 571.844
• DOI: 10.1016/j.cyto.2020.155052
• Languages: English
• ISSNs: 1043-4666

Abstract

Graphical abstract: Possible influence genotypic combinations of polymorphisms in TLR9 -1237T/T and -1486C/T on the profile of cytokines in HCV patients, treated with DAAs . Highlights: TLR gene polymorphisms are reported as markers of cancer risk. 151 HCV patients participated in study, segregated into ≤F2 and >F2 hepatic fibrosis. A significant increase of IL-10 were observed in HCV >F2 compared to ≤F2 patients. TLR9 -1237T/T and -1486C/T seem to influence the dynamics of cytokines profile. Abstract: Hepatitis C is a public health problem and affects approximately 3% of the world's population. HCV infections have a wide spectrum of clinical manifestations, and several single nucleotide polymorphisms (SNPs) in the genes of the toll-like receptors are cited to influence the clinical outcomes. A cross-sectional study was conducted in the Amazonas State, Brazil in which SNPs in TLR4 and TLR9 genes were genotyped by PCR-RFLP in 151 HCV chronic liver disease patients and 206 healthy donors. The circulating cytokines IL-6, TNF, IL-10, IL-2, IFN-γ, IL-4 and IL-17A were measured by cytometric bead array (CBA) which revealed that the combined genotypes of TLR9 -1237T/T and -1486C/T seem to influence the cytokine profile under lipopolysaccharide (LPS) stimulation of the Th17 profile, especially among patients with advanced chronic liver disease when treated with DAAs.